Skip to main content

Table 1 Baseline characteristic by treatment group (N = 13,438)

From: Adherence patterns in naïve and prevalent use of infliximab and its biosimilar

 

INF biosimilar (Inflectra)

INF bio-originator (Infliximab)

P-Value

N = 319

N = 13,119

Naïve

Prevalent

Naïve

Prevalent

Number of patients

96

223

2,149

10,970

 

Age, N (%)a

    

 < 0.0001*

 < 35

24 (25.0)

38 (17.0)

581 (27.0)

2,629 (24.0)

 

 35–44

14 (14.6)

30 (13.5)

429 (20.0)

1,935 (17.6)

 

 45–54

21 (21.9)

43 (19.3)

473 (22.0)

2,571 (23.4)

 

 55–64

27 (28.1)

57 (25.6)

503 (23.4)

2,706 (24.7)

 

 ≥ 65

10 (10.4)

55 (24.7)

163 (7.6)

1,129 (10.3)

 

Female, N (%)

63 (65.6)

135 (60.5)

1,330 (61.9)

6,254 (57.0)

0.0001*

Region, N (%) a

    

 < 0.0001*

 Mid-West

8 (8.3)

55 (24.7)

402 (18.7)

2,225 (20.3)

 

 North-East

5 (5.2)

10 (4.5)

351 (16.3)

1,808 (16.5)

 

 South

32 (33.3)

65 (29.2)

849 (39.5)

4,403 (40.1)

 

 West

29 (30.2)

71 (31.8)

257 (12.0)

1,318 (12.0)

 

 Unknown

22 (22.9)

22 (9.9)

290 (13.5)

1,216 (11.1)

 

All-cause hospitalization, N (%)

27 (28.1)

39 (17.5)

615 (28.6)

1,466 (13.4)

 < 0.0001*

Infections, N (%)

58 (60.4)

121 (54.3)

1,375 (63.9)

6,284 (57.3)

 < 0.0001*

Any hospitalized infection during follow-up, N (%)

0 (0.0)

6 (2.7)

108 (5.0)

528 (4.8)

 < 0.0001*

Autoimmune disease, N (%) a

    

 < 0.0001*

 Rheumatoid arthritis (RA)

51 (53.1)

111 (49.8)

805 (37.5)

4292 (39.1)

 

 Psoriatic arthritis (PsA)

9 (9.4)

23 (10.3)

125 (5.8)

919 (8.4)

 

 Inflammatory bowel disease (IBD)

36 (37.5)

78 (35.0)

1,049 (48.8)

4,977 (45.4)

 

 Others

-

11 (4.9)

170 (7.9)

782 (7.1)

 

Comorbidities, N (%)

 Cancer

5 (5.2)

6 (2.7)

83 (3.9)

261 (2.4)

0.0012*

 Chronic kidney disease

10 (10.4)

22 (9.9)

210 (9.8)

938 (8.6)

0.2721

 Chronic obstructive pulmonary disease

15 (15.6)

19 (8.5)

160 (7.5)

727 (6.6)

0.0087*

 Chronic heart disease

4 (4.2)

21 (9.4)

105 (4.9)

505 (4.6)

0.0278*

 Depression

14 (14.6)

32 (14.4)

341 (15.9)

1,318 (12.0)

 < 0.0001*

 Diabetes

9 (9.4)

37 (16.6)

271 (12.6)

1,275 (11.6)

0.0838

Number of other baseline biologics, N (%)

    

 < 0.0001*

 None

56 (58.3)

198 (88.8)

1,260 (58.6)

9,777 (89.1)

 

 One

24 (25.0)

21(9.4)

647 (30.1)

976 (8.9)

 

 Two or more

16 (16.7)

4 (1.8)

242 (11.3)

217 (2.0)

 

Concurrent medications, N (%)

 Antibiotics

70 (72.9)

144 (64.6)

1,572 (73.2)

7,003 (63.8)

 < 0.0001*

 Betablockers

19 (19.8)

43 (19.3)

309 (14.4)

1,547 (14.1)

0.0839

 Hormone therapy

17 (17.7)

37 (16.6)

378 (17.6)

1,608 (14.7)

0.0060*

 Opioids

56 (58.3)

115 (51.6)

1,128 (52.5)

4,608 (42.0)

 < 0.0001*

 Nonsteroidal anti-inflammatory drugs (NSAID)

37 (38.5)

67 (30.0)

660 (30.7)

2801 (25.5)

 < 0.0001*

 Statin

16 (16.7)

69 (30.9)

399 (18.6)

2206 (20.1)

0.0003*

 Steroids

73 (76.0)

75 (33.6)

1,608 (74.8)

4,377 (39.9)

 < 0.0001*

  1. Baseline was two years to the index date
  2. * indicates the p-value ≤ 0.05
  3. aEstimations were done with one-way ANOVA for ordinal variables and Chi-Square for other variables